Company profile
Johnson & Johnson
Diversified pharma
Share price · JNJ
$271.11+42.19 (+18.43%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(46 total)
46Total Assets
30Approved
6Phase 3 / Filed
10Phase 1–2 / Early
18Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFR x c-METMonoclonal antibody | Non-Small Cell Lung Cancer | |
Bosentan(Tracleer) | Approved | Endothelin receptor (ETA/ETB, dual)Small molecule | Hypertension |
Canagliflozin(Invokana) | Approved | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
| Approved | ProteasomeSmall molecule | Multiple Myeloma | |
| Approved | BCMACell therapy | Multiple Myeloma | |
| Approved | CD38Monoclonal antibody | Multiple Myeloma | |
Darunavir(Prezista) | Approved | HIV proteaseSmall molecule | HIV |
Esketamine(Spravato) | Approved | NMDA receptorSmall molecule | Major Depressive Disorder |
Etravirine(Intelence) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
golimumab(Simponi) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseaseRheumatoid Arthritis Ulcerative Colitis |
guselkumab(Tremfya) | Approved | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseaseAtopic DermatitisPsoriasis Ulcerative Colitis, Crohn's Disease |
| Approved | Dopamine D2 receptor (antagonist)Small molecule | SchizophreniaEpilepsy | |
| Approved | IL-23 receptorPeptide | Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis, Crohn's Disease | |
infliximab(Remicade) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
| Approved | EGFRSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.